Skip to content
Branch: master
Find file History
Fetching latest commit…
Cannot retrieve the latest commit at this time.
Permalink
Type Name Latest commit message Commit time
..
Failed to load latest commit information.
R
documents
extras
inst
man
.Rbuildignore
.gitignore
AhasHfBkleAmputation.Rproj
DESCRIPTION
NAMESPACE
readme.md

readme.md

Comparison of Canagliflozin vs. Alternative Antihyperglycemic Treatments

on Risk of Heart Failure Hospitalization and Amputation for Patients with Type 2 Diabetes Mellitus and the Subpopulation with Established Cardiovascular Disease

Recent studies have suggested that SGLT2 inhibitors may reduce the risk of cardiovascular events, relative to placebo, and SGLT2i drugs may lower risk of hospitalization for heart failure and all-cause mortality relative to other glucose lowering drugs. However, there are limited head-to-head comparisons that provide a real-world perspective of the safety and effectiveness of canagliflozin relative to other drugs in the SGLT2i class or alternative therapies. This study aims to examine the comparative effects of canagliflozin vs. other alternative treatments for T2DM, overall and within the subpopulation of patients with established cardiovascular diseases, across 4 US administrative claims databases. We will study 2 health outcomes {1) hospitalization for heart failure, and 2) below knee lower extremity amputation }, amongst new users of canagliflozin vs. new users of {1) empagliflozin, 2) dapagliflozin, 3) empagliflozin or dapagliflozin, 4) any DPP-4 inhibitor, GLP-1 agonist or other select AHA, 5) any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin or other select AHAs } and amongst new users of empagliflozin or dapagliflozin vs. new users of {1) any DPP-4 inhibitor, GLP-1 agonist or other select AHA, 2) any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin or other select AHAs} for patients with T2DM, overall and in the subpopulation with established cardiovascular diseases. We will perform clinical characterization to descriptively summarize and compare the exposure populations, and perform population-level effect estimation analyses for comparative effectiveness and safety.

Package overview

Location Content
documents/ The protocol and statistical analysis plan.
extras/InstallPackages.R R code for installing the required dependencies.
inst/settings/rEnvironmentSnapshot.csv An exhaustive list of the version numbers of the software used when executing the study.
root folder The R package for executing the study. Needs to be built before executing.
extras/CodeToRun.R The code used to execute the study in the JnJ environment.
extras/EvidenceExplorer The source code for the Shiny app for exploring the study results. Requires all files from the shinyData folders created when running the package to be placed in a data subfolder of the app.

License

The AhasHfBkleAmputation package is licensed under Apache License 2.0

Development

AhasHfBkleAmputation was developed in R Studio.

Development status

Study has been executed

You can’t perform that action at this time.
You signed in with another tab or window. Reload to refresh your session. You signed out in another tab or window. Reload to refresh your session.